Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2026Frontiers in Molecular BiosciencesOpen Access

Heterogeneous regulation of fibroblast growth factor 23 in acute kidney injury, chronic kidney disease, and polycystic kidney disease: mechanisms, diagnostic utility, and clinical implications

View Full Paper
Ask AI
Bookmark
Share

Authors

YFYong FengBYBo YangHCHaimin Chen

Discussion

Loading...

Member takes

Overview

This review explores FGF23 regulation in kidney diseases, highlighting its diagnostic value and therapeutic potential.

Key Points

  • This review aims to dissect the complex regulation of FGF23 in acute kidney injury, chronic kidney disease, and polycystic kidney disease.
  • Examined the expression and dynamics of FGF23 across AKI, CKD, and ADPKD.
  • Discussed molecular mechanisms driving FGF23 levels in different kidney conditions.
  • Reviewed clinical implications and potential therapeutic approaches related to FGF23.
  • FGF23 elevation varies significantly among AKI, CKD, and ADPKD, reflecting unique regulatory mechanisms.
  • In AKI, factors like inflammation and metabolic stress cause rapid FGF23 increases.
  • CKD is characterized by sustained FGF23 elevation due to phosphate retention and Klotho deficiency.
  • ADPKD shows early FGF23 increases potentially linked to ectopic production and tubular defects.

Cite This Study

Feng et al. (2026) studied this question.

synapsesocial.com/papers/6997f941ad1d9b11b34522fbhttps://doi.org/10.3389/fmolb.2026.1764206
View Full Paper
Ask AI
Bookmark
Share